<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JPP</journal-id>
<journal-id journal-id-type="hwp">spjpp</journal-id>
<journal-title>Journal of Pharmacy Practice</journal-title>
<issn pub-type="ppub">0897-1900</issn>
<issn pub-type="epub">1531-1937</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0897190011431631</article-id>
<article-id pub-id-type="publisher-id">10.1177_0897190011431631</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Overview of Supportive Care in Patients Receiving Chemotherapy</article-title>
<subtitle>Antiemetics, Pain Management, Anemia, and Neutropenia</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Scialdone</surname>
<given-names>Liana</given-names>
</name>
<degrees>BS, PharmD (Candidate 2012)</degrees>
<xref ref-type="aff" rid="aff1-0897190011431631">1</xref>
<xref ref-type="corresp" rid="corresp1-0897190011431631"/>
</contrib>
</contrib-group>
<aff id="aff1-0897190011431631">Albany College of Pharmacy and Health Sciences, Albany, NY, USA</aff>
<author-notes>
<corresp id="corresp1-0897190011431631">Liana Scialdone, Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, Albany, NY 12208, USA Email: <email>liana.scialdone@acphs.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2012</year>
</pub-date>
<volume>25</volume>
<issue>2</issue>
<fpage>209</fpage>
<lpage>221</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>With advancements in the field of oncology, more and more people are living with cancer. The prevalence of invasive cancer in the United States is estimated to be almost 12 million. The treatment of cancer as well as the malignancy itself can cause an immense number of side effects and other complications. This article explores the fundamentals of supportive care in patients receiving chemotherapy and radiation treatment including prevention of nausea and vomiting, pain management, treatment of anemia and neutropenia. Proper supportive care can help improve clinical outcomes, reduce medical costs, and help patients with cancer live longer, happier, and healthier lives. For these reasons, it is important for pharmacists to possess a solid understanding of how to prevent and treat the adverse effects of chemotherapy and radiation treatment.</p>
</abstract>
<kwd-group>
<kwd>chemotherapy supportive care</kwd>
<kwd>antiemetics</kwd>
<kwd>pain management</kwd>
<kwd>anemia</kwd>
<kwd>neutropenia</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0897190011431631">
<title>Introduction</title>
<p>According to the US National Cancer Institute's Surveillance Epidemiology and End Results (SEER) database for the year 2007, about 11 714 000 people are estimated to be living with invasive cancer in the United States.<sup>
<xref ref-type="bibr" rid="bibr1-0897190011431631">1</xref>
</sup> The most common types of cancer are prostate cancer in men and breast cancer in women.<sup>
<xref ref-type="bibr" rid="bibr2-0897190011431631">2</xref>
</sup> Life expectancies vary depending on the type of cancer, stage at which it was diagnosed, age and comorbidities of the patient. Common treatment modalities include surgery, chemotherapy, radiation, targeted therapy, and immunotherapy, among others. The treatment of cancer (as well as the malignancy itself) can cause an immense number of side effects and other medical issues. Examples of the physical and emotional problems associated with cancer and the treatment of cancer include hair loss, nausea and vomiting, fatigue, pain, weight loss or weight gain, depression, bowel irregularities, peripheral neuropathy, sexual and fertility problems, anemia, urine and kidney problems, thrombocytopenia, and neutropenia.<sup>
<xref ref-type="bibr" rid="bibr3-0897190011431631">3</xref>
</sup> In addition, the financial costs of cancer are great for both the patient and the health care community. The National Institutes of Health estimated that in 2010, the overall annual cost of cancer was about $263.8 billion (including direct medical costs as well as indirect morbidity and mortality costs).<sup>
<xref ref-type="bibr" rid="bibr2-0897190011431631">2</xref>
</sup>
</p>
<p>Supportive care in patients with cancer is almost equally as important as the treatment itself. Adverse effects such as severe vomiting or neutropenia can necessitate a delay in subsequent treatment cycles or a reduction in dose, contributing to poor clinical outcomes.<sup>
<xref ref-type="bibr" rid="bibr4-0897190011431631">4</xref>
<xref ref-type="bibr" rid="bibr5-0897190011431631"/>–<xref ref-type="bibr" rid="bibr6-0897190011431631">6</xref>
</sup> Additionally, adverse drug effects are responsible for a substantial amount of health care costs.<sup>
<xref ref-type="bibr" rid="bibr7-0897190011431631">7</xref>
</sup> Perhaps most importantly, without proper supportive care, chemotherapy can make patients feel extremely sick, miserable, and unable to live a “normal” life. Good supportive care is especially important in patients with end-stage cancers receiving palliative chemotherapy or radiation. With a limited quantity of time left to live, it is critical to help these patients improve their quality of life.</p>
</sec>
<sec id="section2-0897190011431631">
<title>Antiemetics</title>
<p>Cancer patients beginning treatment with chemotherapy or radiation often list nausea and vomiting as one of their greatest fears.<sup>
<xref ref-type="bibr" rid="bibr8-0897190011431631">8</xref>
<xref ref-type="bibr" rid="bibr9-0897190011431631"/>–<xref ref-type="bibr" rid="bibr10-0897190011431631">10</xref>
</sup> Chemotherapy-induced nausea and vomiting (CINV) can significantly affect a patient’s quality of life, leading to poor compliance with further chemotherapy treatments.<sup>
<xref ref-type="bibr" rid="bibr5-0897190011431631">5</xref>
</sup> CINV can also cause metabolic imbalances, nutritional depletion, anorexia, and decline of the patient’s performance and mental status.<sup>
<xref ref-type="bibr" rid="bibr4-0897190011431631">4</xref>,<xref ref-type="bibr" rid="bibr11-0897190011431631">11</xref>
</sup> More than 90% of patients receiving highly emetogenic chemotherapy will experience episodes of vomiting. However, this number is reduced to 30% when the patient receives proper prophylactic antiemetic treatments.<sup>
<xref ref-type="bibr" rid="bibr12-0897190011431631">12</xref>
</sup>
</p>
<sec id="section3-0897190011431631">
<title>Risk Factors</title>
<p>The main factor contributing to the likelihood of emesis is the emetogenic potential of the drug<sup>
<xref ref-type="bibr" rid="bibr8-0897190011431631">8</xref>,<xref ref-type="bibr" rid="bibr13-0897190011431631">13</xref>
</sup> (<xref ref-type="table" rid="table1-0897190011431631">Table 1</xref>). Other factors that can contribute to the incidence or severity of nausea and vomiting include dose, coadministration of other agents, and target of radiation therapy (thorax, head and neck, and upper abdomen are associated with the highest incidence).<sup>
<xref ref-type="bibr" rid="bibr14-0897190011431631">14</xref>
</sup> Patient-related factors that increase the risk of emesis include female gender, younger age (less than 40),<sup>
<xref ref-type="bibr" rid="bibr8-0897190011431631">8</xref>,<xref ref-type="bibr" rid="bibr15-0897190011431631">15</xref>
</sup> prior history of CINV, high pretreatment expectations, weight loss &gt;5%, and presence of a percutaneous endoscopic gastrostomy.<sup>
<xref ref-type="bibr" rid="bibr16-0897190011431631">16</xref>
</sup> On the other hand, patients with a history of alcoholism have a lower risk of emesis when receiving chemotherapy.<sup>
<xref ref-type="bibr" rid="bibr15-0897190011431631">15</xref>
</sup>
</p>
<table-wrap id="table1-0897190011431631" position="float">
<label>Table 1.</label>
<caption>
<p>Emetogenic Levels of IV Administered Chemotherapy Drugs in the Absence of Antiemetic Prophylaxis<sup>
<xref ref-type="bibr" rid="bibr8-0897190011431631">8</xref>,<xref ref-type="bibr" rid="bibr13-0897190011431631">13</xref>
</sup>
</p>
</caption>
<graphic alternate-form-of="table1-0897190011431631" xlink:href="10.1177_0897190011431631-table1.tif"/>
<table>
<tbody>
<tr>
<td>Level 1 (minimal risk, &lt;10%)</td>
<td>Level 2 (low risk, 10%-30%)</td>
<td>Level 3 (moderate risk, 31%-90%)</td>
<td>Level 4 (high risk, &gt;90%) </td>
</tr>
<tr>
<td>Bevacizumab Blemoycin Busulfan Cladribine Fludarabine Vinblastine Vincristine Vinorelbine</td>
<td>Bortezomib Cetuximab Cytarabine (≤100 mg/m<sup>2</sup> BSA) Docetaxel Etoposide Fluorouracil Gemcitabine Ixabepilone Lapatinib Methotrexate Mitomycin Mitoxantrone Paclitaxel Pemetrexed Temsirolimus Topotecan Trastuzumab </td>
<td>Carboplatin Cyclophosphamide (≤1.5 g/m<sup>2</sup>) Cytarabine (&gt;1 g/m2) Daunorubicin Doxorubicin Epirubicin Idarubicin Ifosfamide Irinotecan Oxaliplatin </td>
<td>Carmustine Cisplatin Cyclophosphamide (&gt;1.5 g/m<sup>2</sup>) Dacarbazine Mechlorethamine Streptozocin </td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section4-0897190011431631">
<title>Prevention</title>
<p>The primary goal with antiemetic therapy is the prevention of emesis. The guidelines for prevention are only for the first dose of chemotherapy (<xref ref-type="table" rid="table2-0897190011431631">Table 2</xref>) and subsequent cycles should be adjusted based on response and use of breakthrough medications.<sup>
<xref ref-type="bibr" rid="bibr14-0897190011431631">14</xref>
</sup> The risk of emesis lasts for at least 3 days for high-risk agents and 2 days for moderate-risk agents after the last dose of chemotherapy is given.<sup>
<xref ref-type="bibr" rid="bibr14-0897190011431631">14</xref>
</sup> Patients need to be protected throughout the entire period. Emesis occurring within the first 24 hours after the dose is defined as acute and emesis occurring more than 24 hours after is considered delayed.<sup>
<xref ref-type="bibr" rid="bibr17-0897190011431631">17</xref>
</sup> Selection of antiemetics is based on the emetic risk of the regimen, prior experience with antiemetics, and patient-specific factors.<sup>
<xref ref-type="bibr" rid="bibr13-0897190011431631">13</xref>
</sup> A list of commonly used agents and usual doses can be found in <xref ref-type="table" rid="table3-0897190011431631">Table 3</xref>. For multidrug regimens, practitioners should select the antiemetic therapy based on the drug which has the highest risk of emesis.<sup>
<xref ref-type="bibr" rid="bibr14-0897190011431631">14</xref>
</sup> It is important to note that oral and intravenous 5-HT3 antagonists have equal efficacy when used at the appropriate dose.<sup>
<xref ref-type="bibr" rid="bibr12-0897190011431631">12</xref>,<xref ref-type="bibr" rid="bibr18-0897190011431631">18</xref>
</sup> Practitioners should also consider using an H2-blocker or proton pump inhibitor (PPI) to prevent dyspepsia, which can mimic nausea.<sup>
<xref ref-type="bibr" rid="bibr14-0897190011431631">14</xref>
</sup> Lifestyle measures can also help prevent nausea and vomiting such as eating small, frequent meals, choice of food, and eating food at room temperature.<sup>
<xref ref-type="bibr" rid="bibr14-0897190011431631">14</xref>
</sup>
</p>
<table-wrap id="table2-0897190011431631" position="float">
<label>Table 2.</label>
<caption>
<p>Recommendations for Prevention of Nausea and Vomiting Prior to the First Round of Intravenous Chemotherapy Based on the Risk of Emesis<sup>
<xref ref-type="bibr" rid="bibr14-0897190011431631">14</xref>
</sup>
</p>
</caption>
<graphic alternate-form-of="table2-0897190011431631" xlink:href="10.1177_0897190011431631-table2.tif"/>
<table>
<thead>
<tr>
<th>Risk of Emesis</th>
<th>Pre-Chemo (Day 1)</th>
<th>Days 2-4 (High) Days 2-3 (Moderate)</th>
</tr>
</thead>
<tbody>
<tr>
<td>High (&gt;90%)</td>
<td>Aprepitant + 5-HT3 + dexamethasone</td>
<td>Aprepitant × 2 days + Dexamethasone daily</td>
</tr>
<tr>
<td>Moderate (30-90%)</td>
<td>Same as high for some or 5-HT3 only for most</td>
<td>Same as high or dexamethasone alone or 5-HT3 alone</td>
</tr>
<tr>
<td>Low (10-30%)</td>
<td>Dexamethasone only or prochlorperazine or Metoclopramide</td>
<td>Nothing required </td>
</tr>
<tr>
<td>Minimal (&lt;10%)</td>
<td>Nothing required </td>
<td>Nothing required</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="table3-0897190011431631" position="float">
<label>Table 3.</label>
<caption>
<p>Common Antiemetics Used for Prevention of Chemotherapy-Induced Nausea and Vomiting<sup>
<xref ref-type="bibr" rid="bibr14-0897190011431631">14</xref>
</sup>
</p>
</caption>
<graphic alternate-form-of="table3-0897190011431631" xlink:href="10.1177_0897190011431631-table3.tif"/>
<table>
<thead>
<tr>
<th>Drug</th>
<th>Class</th>
<th>Dosing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aprepitant (Emend)</td>
<td>NK1 and substance P inhibitor</td>
<td>125 mg po pre-chemo, then 80 mg po daily on days 2-4  </td>
</tr>
<tr>
<td>Fosaprepitant (Emend for injection)</td>
<td>NK1 and substance P inhibitor</td>
<td>115 mg IV pre-chemo followed by 80 mg oral aprepitant as above</td>
</tr>
<tr>
<td>Ondansetron (Zofran)</td>
<td>5-HT3 antagonist</td>
<td>8 mg IV or 16 mg po pre-chemo, then 8 mg po BID or 16 mg po daily on days 2-4 </td>
</tr>
<tr>
<td>Granisetron (Kytril)</td>
<td>5-HT3 antagonist</td>
<td>1 mg IV pre-chemo, then 1 mg po BID or 2 mg po daily on days 2-4 </td>
</tr>
<tr>
<td>Dolasetron (Anzemet)</td>
<td>5-HT3 antagonist</td>
<td>100 mg IV pre-chemo, then 100 mg po daily on days 2-4</td>
</tr>
<tr>
<td>Palonosetron (Aloxi) </td>
<td>5-HT3 antagonist</td>
<td>0.25 mg IV pre-chemo or 0.5 mg po pre-chemo (lasts 3 days) </td>
</tr>
<tr>
<td>Dexamethasone (Decadron) </td>
<td>Corticosteroid</td>
<td>12 mg po/IV pre-chemo, then 12 mg po/IV daily on days 2-4 (high risk) and days 2-3 (moderate risk) </td>
</tr>
<tr>
<td>Prochlorperazine (Compazine) </td>
<td>Phenothiazine</td>
<td>10 mg po q4-6h prn or 25 mg pr q12h prn </td>
</tr>
<tr>
<td>Metoclopramide (Reglan) </td>
<td>
</td>
<td>10-40 mg po/IV q4-6h</td>
</tr>
<tr>
<td>Lorazepam (Ativan) </td>
<td>Benzodiazepine</td>
<td>1 mg po/IV pre-chemo and q8h prn </td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0897190011431631">
<p>Abbreviations: IV intravenous; po, orally; BID, twice daily; prn, as needed; pr, per rectal route; q, every.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section5-0897190011431631">
<title>Breakthrough</title>
<p>Emesis that occurs even with the administration of antiemetic agents is called breakthrough nausea and vomiting. In this situation, it is recommended to give an additional agent from a different class rather than increasing the dose of the initial drug/drugs.<sup>
<xref ref-type="bibr" rid="bibr19-0897190011431631">19</xref>
</sup> No single drug class has been shown to be superior and patients may require multiple drugs with different mechanisms of action.<sup>
<xref ref-type="bibr" rid="bibr20-0897190011431631">20</xref>
</sup> It is also highly recommended to schedule routine continuous dosing rather than PRN (as needed). The oral route of administration is not likely to be feasible due to ongoing vomiting and therefore it might be necessary to administer drugs via the rectal, intravenous, buccal, sublingual, or transdermal route. Patients experiencing frequent breakthrough nausea and vomiting should be put on sustained-release medications. Additionally, the next cycle of chemotherapy should be treated as if it were one level higher in regard to the risk of emesis. If the treatment goal is palliative, consider changing the chemotherapy or reducing the dose. Prior to administration of next cycle, patients should be reassessed for possible nonchemotherapy-related reasons for emesis such as brain metastases, electrolyte abnormalities, tumor infiltration of the bowel, or other GI issues. Finally, it is crucial to keep patients hydrated and check fluid and electrolyte levels.<sup>
<xref ref-type="bibr" rid="bibr14-0897190011431631">14</xref>
</sup>
</p>
</sec>
<sec id="section6-0897190011431631">
<title>Anticipatory</title>
<p>Anticipatory nausea and vomiting is a conditioned response that occurs before a patient receives the next dose of chemotherapy due to a negative past experience.<sup>
<xref ref-type="bibr" rid="bibr21-0897190011431631">21</xref>
</sup> Behavioral therapy such as systemic desensitization, hypnosis with guided imagery, relaxation techniques, as well as acupuncture can be helpful.<sup>
<xref ref-type="bibr" rid="bibr21-0897190011431631">21</xref>
<xref ref-type="bibr" rid="bibr22-0897190011431631"/>
<xref ref-type="bibr" rid="bibr23-0897190011431631"/>–<xref ref-type="bibr" rid="bibr24-0897190011431631">24</xref>
</sup> Antianxiety agents such as lorazepam and alprazolam have also been proven effective.<sup>
<xref ref-type="bibr" rid="bibr14-0897190011431631">14</xref>,<xref ref-type="bibr" rid="bibr25-0897190011431631">25</xref>
</sup>
</p>
</sec>
</sec>
<sec id="section7-0897190011431631">
<title>Pain Management</title>
<p>Pain is commonly experienced in patients with cancer. It is one of the symptoms patients fear the most. Cancer pain occurs in about 25% of patients with newly diagnosed malignancies, 33% of patients undergoing treatment, and 75% of patients with advanced disease.<sup>
<xref ref-type="bibr" rid="bibr26-0897190011431631">26</xref>,<xref ref-type="bibr" rid="bibr27-0897190011431631">27</xref> </sup>Persistent pain greatly impacts patients’ ability to interact with family and friends and decreases overall quality of life.<sup>
<xref ref-type="bibr" rid="bibr28-0897190011431631">28</xref>
</sup>
</p>
<sec id="section8-0897190011431631">
<title>Cancer Pain Assessment</title>
<p>A formal comprehensive pain assessment must first be performed. Since pain is subjective, a patient’s self-report is critical.<sup>
<xref ref-type="bibr" rid="bibr29-0897190011431631">29</xref>
</sup> Examples of components that should be included in a pain assessment are listed in <xref ref-type="fig" rid="fig1-0897190011431631">Figure 1</xref>. Reassessment of pain intensity should be performed at specified intervals to ensure the treatment achieves the desired effect. In addition, psychosocial support should be available and educational materials must be provided to the patient.<sup>
<xref ref-type="bibr" rid="bibr26-0897190011431631">26</xref>,<xref ref-type="bibr" rid="bibr30-0897190011431631">30</xref>
</sup>
</p>
<fig id="fig1-0897190011431631" position="float">
<label>Figure 1.</label>
<caption>
<p>Components of a cancer pain assessment.<sup>
<xref ref-type="bibr" rid="bibr29-0897190011431631">29</xref>
</sup>
<sup>-</sup>
<sup>
<xref ref-type="bibr" rid="bibr31-0897190011431631">31</xref>
</sup>
</p>
</caption>
<graphic alternate-form-of="fig1-0897190011431631" xlink:href="10.1177_0897190011431631-fig1.tif"/>
</fig>
</sec>
<sec id="section9-0897190011431631">
<title>General Principles of Pain Management With Opioid Therapy</title>
<p>Before treating a cancer patient with opioid therapy, it is important to first determine whether the pain is due to an oncological emergency (fracture, brain, epidural, or leptomeningeal metastases, pain related to infection, or obstructed or perforated viscus). If an emergency exists, practitioners should treat the underlying condition with surgery, antibiotics, radiation, and so on.<sup>
<xref ref-type="bibr" rid="bibr30-0897190011431631">30</xref>
</sup>
</p>
<p>Pain management regimens vary depending on the severity of the pain, which is subjective to the patient. Severe pain should be treated with rapid titration of short-acting opioids because they have the advantage of rapid onset of analgesic effect. Moderate pain should be treated similar to severe pain, beginning with slower titration of short-acting opioids. Mild pain should be treated with nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, or a very slow titration of short-acting opioids.<sup>
<xref ref-type="bibr" rid="bibr30-0897190011431631">30</xref>
</sup>
</p>
<p>There are different treatment algorithms for opioid-naive (<xref ref-type="fig" rid="fig2-0897190011431631">Figure 2</xref>) and opioid-tolerant patients (<xref ref-type="fig" rid="fig3-0897190011431631">Figure 3</xref>).<sup>
<xref ref-type="bibr" rid="bibr30-0897190011431631">30</xref>
</sup> According to the US Food and Drug Administration (FDA), patients considered opioid tolerant are those taking at least 60 mg oral morphine/d, 25 mcg transdermal fentanyl/h, 30 mg oral oxycodone/d, 8 mg hydromorphone/d, 25 mg oral oxymorphone/d, or an equianalgesic dose of another opioid for at least 1 week.<sup>
<xref ref-type="bibr" rid="bibr32-0897190011431631">32</xref>
</sup>
</p>
<fig id="fig2-0897190011431631" position="float">
<label>Figure 2.</label>
<caption>
<p>Initiation and management of opioid therapy in opioid-naive cancer patients.<sup>
<xref ref-type="bibr" rid="bibr30-0897190011431631">30</xref>
</sup>
</p>
</caption>
<graphic alternate-form-of="fig2-0897190011431631" xlink:href="10.1177_0897190011431631-fig2.tif"/>
</fig>
<fig id="fig3-0897190011431631" position="float">
<label>Figure 3.</label>
<caption>
<p>Guidelines for administration of opioids in opioid-tolerant patients.<sup>
<xref ref-type="bibr" rid="bibr30-0897190011431631">30</xref>
</sup>
</p>
</caption>
<graphic alternate-form-of="fig3-0897190011431631" xlink:href="10.1177_0897190011431631-fig3.tif"/>
</fig>
<p>An appropriate dose is that which relieves pain for the entire dosing interval without causing unmanageable side effects. The route of administration is decided based upon how to best suit the patient’s ongoing analgesic needs. The oral route is preferred in patients receiving chronic opioid therapy.<sup>
<xref ref-type="bibr" rid="bibr33-0897190011431631">33</xref>
<xref ref-type="bibr" rid="bibr34-0897190011431631"/>–<xref ref-type="bibr" rid="bibr35-0897190011431631">35</xref>
</sup> Intravenous (IV) or subcutaneous (SQ) is recommended for patients who cannot swallow or absorb opioids enterally. The parenteral route is recommended when faster analgesia is required (peak time 15 minutes compared to 60 minutes with oral dosing).<sup>
<xref ref-type="bibr" rid="bibr36-0897190011431631">36</xref>
</sup>
</p>
<p>Methods of analgesic administration widely used in clinical practice include “around the clock,” “as needed,” and “patient-controlled analgesia.” Around-the-clock dosing is provided to chronic pain patients that require continuous pain relief. A “rescue dose” of a short-acting opioid should be provided for pain that is not relieved by regularly scheduled doses (breakthrough pain). As needed dosing is used in patients who have intermittent pain with pain-free periods. Patient-controlled analgesia allows patient to control a device that delivers a bolus of pain medication on demand.<sup>
<xref ref-type="bibr" rid="bibr30-0897190011431631">30</xref>
</sup>
</p>
<p>When choosing an opioid for pain relief, short half-life opioid agonists are preferred (morphine, hydromorphone, fentanyl, and oxycodone) because they are more easily titrated than long half-life anagesics (methadone and levorphanol).<sup>
<xref ref-type="bibr" rid="bibr37-0897190011431631">37</xref>
</sup> Transdermal fentanyl is not indicated for initial opioid therapy and should only be used after pain is controlled by other opioids.<sup>
<xref ref-type="bibr" rid="bibr38-0897190011431631">38</xref>
</sup> Morphine is generally considered the initial opioid of choice.<sup>
<xref ref-type="bibr" rid="bibr39-0897190011431631">39</xref>
</sup> However, it should be avoided in patients with renal and hepatic insufficiency because the active metabolite, morphine 6-glucuronide may accumulate and contribute to adverse effects.<sup>
<xref ref-type="bibr" rid="bibr40-0897190011431631">40</xref>,<xref ref-type="bibr" rid="bibr41-0897190011431631">41</xref>
</sup> Practitioners should also be cautious when using methadone due to its variable pharmacokinetics (half-life can range from 8 to more than 120 hours) and high potency. Methadone should be started at lower doses and slowly titrated up with the addition of sufficient short-acting breakthrough pain medications.<sup>
<xref ref-type="bibr" rid="bibr42-0897190011431631">42</xref>
</sup>
</p>
</sec>
<sec id="section10-0897190011431631">
<title>Ongoing Care</title>
<p>Subsequent treatment should be based on patient’s continued pain rating scores. If an acceptable level of comfort and function is achieved, consider converting to an extended-release oral formulation, extended-release transdermal (ie, fentanyl), or other long-acting drug (methadone). Rescue doses of the short-acting formulation of the same opioid may be provided for breakthrough pain. Routine follow-up should be done every day for inpatients, during each outpatient visit, and at each pharmacy appointment.<sup>
<xref ref-type="bibr" rid="bibr30-0897190011431631">30</xref>
</sup>
</p>
</sec>
<sec id="section11-0897190011431631">
<title>Adverse Effects of Opioids</title>
<p>Common side effects of opioids include constipation, nausea and vomiting, pruritis, delirium, respiratory depression, motor and cognitive impairment, and sedation. Constipation can almost always be anticipated and prophylactic bowel regimens should be started simultaneously with initiation of opioid therapy. Prophylactic regimens should include polyethylene glycol (1 capful in 8 oz water twice a day), with or without a stool softener (docusate 2 tablets PO every morning). A stimulant laxative such as senna or bisacodyl may be added later if necessary. Nonpharmacological measures include maintaining adequate hydration, increasing dietary fiber intake, and exercise if feasible. If constipation persists, first rule out bowel obstruction and check for fecal impaction. Consider adding another agent such as magnesium hydroxide, lactulose, sorbitol, or a prokinetic drug such as metoclopramide. If side effects persist, are unmanageable or intolerable, the analgesic dose may be decreased by 25% and the addition of co-analgesics may be considered. Opioid rotation may also be an option.<sup>
<xref ref-type="bibr" rid="bibr43-0897190011431631">43</xref>,<xref ref-type="bibr" rid="bibr44-0897190011431631">44</xref>
</sup>
</p>
</sec>
<sec id="section12-0897190011431631">
<title>Co-Analgesics</title>
<p>Co-analgesics are commonly used to assist in pain management, to reduce overall opioid requirements, and to manage bone pain and neuropathic pain.<sup>
<xref ref-type="bibr" rid="bibr45-0897190011431631">45</xref>
</sup> They consist of a diverse range of drug classes such as anticonvulsants, tricyclic antidepressants, serotonin/norepinephrine reuptake inhibitors, bisphosphonates (especially for bone pain), corticosteroids, NSAIDs, acetaminophen, and local anesthetics (ie, topical lidocaine patch).<sup>
<xref ref-type="bibr" rid="bibr30-0897190011431631">30</xref>
</sup> A noncomprehensive list of co-analgesics that may be used with or without opioids can be found in <xref ref-type="table" rid="table4-0897190011431631">Table 4</xref>.</p>
<table-wrap id="table4-0897190011431631" position="float">
<label>Table 4.</label>
<caption>
<p>Co-Analgesic Medications for Use in Cancer Patients<sup>
<xref ref-type="bibr" rid="bibr30-0897190011431631">30</xref>
</sup>
<sup>,</sup>
<sup>
<xref ref-type="bibr" rid="bibr45-0897190011431631">45</xref>
</sup>
<sup>,</sup>
<sup>
<xref ref-type="bibr" rid="bibr46-0897190011431631">46</xref>
</sup>
</p>
</caption>
<graphic alternate-form-of="table4-0897190011431631" xlink:href="10.1177_0897190011431631-table4.tif"/>
<table>
<thead>
<tr>
<th>Co-Analgesic</th>
<th>Class</th>
<th>Special Indication/Use</th>
<th>Initial Dose</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Desipramine</td>
<td>TCA</td>
<td>Neuropathic pain </td>
<td>10-25 mg nightly</td>
<td>50-300 mg nightly</td>
</tr>
<tr>
<td>Nortriptyline</td>
<td>TCA</td>
<td>Neuropathic pain</td>
<td>10-25 mg nightly</td>
<td>50-150 mg nightly</td>
</tr>
<tr>
<td>Venlafaxine (Effexor)</td>
<td>SNRI</td>
<td>Neuropathic pain</td>
<td>50-75 mg daily</td>
<td>75-225 mg daily</td>
</tr>
<tr>
<td>Duloxetine (Cymbalta)</td>
<td>SNRI</td>
<td>Neuropathic pain</td>
<td>30-60 mg daily </td>
<td>60-120 mg daily</td>
</tr>
<tr>
<td>Gabapentin (Neurontin)</td>
<td>Anticonvulsant</td>
<td>Neuropathic pain</td>
<td>300 mg TID</td>
<td>900 mg TID-QID</td>
</tr>
<tr>
<td>Pregabalin (Lyrica) </td>
<td>Anticonvulsant</td>
<td>Neuropathic pain</td>
<td>50 mg TID </td>
<td>100 mg TID</td>
</tr>
<tr>
<td>Ibuprofen</td>
<td>NSAID</td>
<td>Arthritic or musculoskeletory pain and inflammation, bone pain</td>
<td>400 mg QID</td>
<td>600-800 mg QID  </td>
</tr>
<tr>
<td>Celecoxib (Celebrex)</td>
<td>NSAID (COX-2 selective)</td>
<td>Arthritic or musculoskeletory pain and inflammation, bone pain</td>
<td>100 mg BID </td>
<td>200 mg BID</td>
</tr>
<tr>
<td>Pamidronate</td>
<td>Bisphosphonate</td>
<td>Bone pain </td>
<td>60-90 mg infusion q3-4 weeks</td>
<td>_</td>
</tr>
<tr>
<td>Lidocaine 5%  patch</td>
<td>Local anesthetic </td>
<td>Localized pain</td>
<td>1 patch over affected area for up to 12 hours in a 24-hour period </td>
<td>_</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0897190011431631">
<p>Abbreviations: NSAID, nonsteroidal anti-inflammatory drug; COX, cyclooxygenase; BID, twice daily; q, every; QID, four times a day; SNRI, serotonin norepinephrine reuptake inhibitor; TID, thrice a day; TCA, tri-cyclic antidepressant.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section13-0897190011431631">
<title>Nonpharmacological Strategies</title>
<p>Although pharmacological analgesics are considered the cornerstone of cancer pain management, they may not always be adequate and are associated with many side effects. Therefore, the addition of nonpharmocological treatments may be necessary. Examples of physical modalities include physical therapy, massage, heat and/or ice, and acupuncture. Examples of cognitive modalities include hypnosis, guided imagery, relaxation techniques, and distraction training. All of these nonpharmacological interventions may be extremely beneficial adjuncts to pain management with opioid therapy.<sup>
<xref ref-type="bibr" rid="bibr30-0897190011431631">30</xref>
</sup>
</p>
</sec>
</sec>
<sec id="section14-0897190011431631">
<title>Anemia</title>
<p>Anemia is prevalent in 30% to 90% of patients with cancer.<sup>
<xref ref-type="bibr" rid="bibr47-0897190011431631">47</xref>
</sup> In particular, patients with lung cancer and gynecological cancer have a very high incidence of chemotherapy-induced anemia.<sup>
<xref ref-type="bibr" rid="bibr48-0897190011431631">48</xref>,<xref ref-type="bibr" rid="bibr49-0897190011431631">49</xref>
</sup> Etiology of anemia is multifactoral and may be caused by the hematological and myelosuppressive adverse effects of chemotherapy or the malignancy itself.<sup>
<xref ref-type="bibr" rid="bibr50-0897190011431631">50</xref>
</sup> Myelosuppressive effects of cytotoxic agents accumulate over the course of repeated chemotherapy cycles, resulting in a steady increase in the rate of anemia.<sup>
<xref ref-type="bibr" rid="bibr48-0897190011431631">48</xref>
</sup> Chemotherapy drugs induce anemia by inhibiting hematopoiesis in the bone marrow. The malignancy itself can suppress hematopoiesis through bone marrow infiltration as well as produce cytokines that lead to iron sequestration and decreased red blood cell (RBC) production. Chronic blood loss at tumor sites and organ damage can further exacerbate anemia. Other factors include nutritional deficiencies caused by loss of appetite or hemolysis by immune-mediated antibodies.<sup>
<xref ref-type="bibr" rid="bibr50-0897190011431631">50</xref>
</sup>
</p>
<sec id="section15-0897190011431631">
<title>Screening and Evaluation and Target Hemoglobin Level</title>
<p>Since there can be many causes of anemia (other than cancer or chemotherapy), it is important to identify the primary etiology in hopes of correcting the underlying comorbidity. As an initial broad characterization, a complete blood cell count (CBC) must be performed as well as a history and physical. Common complaints of anemic patients include syncope, exercise dyspnea, headache, vertigo, chest pain, major fatigue not relieved by rest, and abnormal menstruation in females.<sup>
<xref ref-type="bibr" rid="bibr51-0897190011431631">51</xref>
</sup> If symptoms of anemia are present, it is necessary to measure hemoglobin levels.</p>
<p>There is a wide range of hemoglobin levels among healthy individuals and therefore a universal “normal” value does not exist. However, most experts agree that a hemoglobin level of less than 11 g/dL or a decrease of 2 g/dL or more from baseline value is the cause for concern and should be evaluated for anemia. The 2007 National Comprehensive Cancer Network guidelines suggest starting treatment in symptomatic patients with hemoglobin levels less than 11 g/dL with a target hemoglobin of 11 to 12 g/dL. The maximum hemoglobin level is 12 g/dL and it is not recommended to go above this.</p>
</sec>
<sec id="section16-0897190011431631">
<title>Red Blood Cell Transfusion</title>
<p>When anemia is diagnosed, it is first necessary to determine whether the patient needs to receive a red blood cell transfusion. As transfusions are controversial, the decision to whether immediate correction of anemia is needed should not be based on a certain hemoglobin level, but rather on an assessment of individual patient characteristics, degree of severity of anemia, the presence and severity of comorbidities, and the clinical judgment of the physician. However, transfusion is rarely indicated when the hemoglobin level is above 10 g/dL.<sup>
<xref ref-type="bibr" rid="bibr51-0897190011431631">51</xref>
</sup> Packed red blood cells (PRBCs) are the blood product of choice for transfusion to correct anemia. The major benefit of transfusion with PRBC is the rapid increase in hemoglobin and hematocrit levels which translates to a rapid improvement in fatigue.<sup>
<xref ref-type="bibr" rid="bibr52-0897190011431631">52</xref>
<xref ref-type="bibr" rid="bibr53-0897190011431631"/>–<xref ref-type="bibr" rid="bibr54-0897190011431631">54</xref>
</sup> Risks associated with PRBC transfusion are transfusion-related reactions, congestive heart failure, bacterial or viral infections, and iron overload.<sup>
<xref ref-type="bibr" rid="bibr55-0897190011431631">55</xref>
</sup> Some studies also found increased risks of venous thromboembolism, arterial thromboembolism, and mortality.<sup>
<xref ref-type="bibr" rid="bibr56-0897190011431631">56</xref>
</sup>
</p>
</sec>
<sec id="section17-0897190011431631">
<title>Erythropoietic Therapy</title>
<p>Red blood cell (RBC) production is normally stimulated by a cytokine produced in the kidneys called erythropoietin. Erythropoietin-stimulating agents (ESAs) are synthetic recombinant human erythropoietin that can stimulate RBC production. These agents can take weeks to initiate a rise in hemoglobin yet are effective at maintaining a target level with repeated administration. The 2 ESAs currently available are epoetin alfa and darbepoetin alfa (both are considered equivalent). However, the use of ESA therapy is controversial because serious adverse effects have started to emerge in recent years.<sup>
<xref ref-type="bibr" rid="bibr51-0897190011431631">51</xref>
</sup> An algorithm to help guide health care providers in determining the proper course of treatment can be found in <xref ref-type="fig" rid="fig4-0897190011431631">Figure 4</xref>.</p>
<fig id="fig4-0897190011431631" position="float">
<label>Figure 4.</label>
<caption>
<p>Erythropoietic therapy treatment algorithm.<sup>
<xref ref-type="bibr" rid="bibr50-0897190011431631">50</xref>
</sup>
</p>
</caption>
<graphic alternate-form-of="fig4-0897190011431631" xlink:href="10.1177_0897190011431631-fig4.tif"/>
</fig>
<p>The main objective of ESA therapy is to reduce the need for transfusion requirements in patients with cancer, and many studies have demonstrated the ability of both epoetin alfa and darbepoetin alfa to achieve this goal.<sup>
<xref ref-type="bibr" rid="bibr57-0897190011431631">57</xref>,<xref ref-type="bibr" rid="bibr58-0897190011431631">58</xref>
</sup> A Cochrane review of 42 randomized controlled clinical trials, which included 6510 patients with cancer, examined the ability of ESA therapy to reduce transfusions. The results of the study showed a decreased relative risk for transfusion in patients receiving ESA.<sup>
<xref ref-type="bibr" rid="bibr59-0897190011431631">59</xref>
</sup> ESA therapy can also provide a gradual improvement in fatigue.<sup>
<xref ref-type="bibr" rid="bibr51-0897190011431631">51</xref>
</sup>
</p>
<p>The major risks of ESA therapy include increased mortality, tumor progression, and thromboembolic events. The black box warning on both epoetin alfa and darbepoetin alfa states that treatment can result in shortened overall survival and decreased time to tumor progression in breast, head and neck, lymphoid, and nonsmall cell lung cancer when dosed to a target hemoglobin of &gt;12 g/dL. However, the risks of shorter survival and time to tumor progression have not been excluded when dosed to a target hemoglobin &lt;12 g/dL.<sup>
<xref ref-type="bibr" rid="bibr60-0897190011431631">60</xref>,<xref ref-type="bibr" rid="bibr61-0897190011431631">61</xref>
</sup> The FDA based this black box warning of 8 randomized trials that individually displayed these results with the use of ESA therapy in certain types of cancer. However, all 8 trials had an off-label target hemoglobin of greater than 12 g/dL.<sup>
<xref ref-type="bibr" rid="bibr62-0897190011431631">62</xref>
<xref ref-type="bibr" rid="bibr63-0897190011431631"/>
<xref ref-type="bibr" rid="bibr64-0897190011431631"/>
<xref ref-type="bibr" rid="bibr65-0897190011431631"/>
<xref ref-type="bibr" rid="bibr66-0897190011431631"/>
<xref ref-type="bibr" rid="bibr67-0897190011431631"/>–<xref ref-type="bibr" rid="bibr68-0897190011431631">68</xref>
</sup> Additionally, there has been conflicting evidence among meta-analyses in regard to the effect of ESA on progression and mortality. Three meta-analyses showed an increased risk while 2 others showed no significant effect.<sup>
<xref ref-type="bibr" rid="bibr69-0897190011431631">69</xref>
<xref ref-type="bibr" rid="bibr70-0897190011431631"/>
<xref ref-type="bibr" rid="bibr71-0897190011431631"/>
<xref ref-type="bibr" rid="bibr72-0897190011431631"/>–<xref ref-type="bibr" rid="bibr73-0897190011431631">73</xref>
</sup> An increased risk of thromboembolic events has also been associated with ESA treatment in patients with cancer, and it has been demonstrated by several meta-analyses.<sup>
<xref ref-type="bibr" rid="bibr69-0897190011431631">69</xref>,<xref ref-type="bibr" rid="bibr71-0897190011431631">71</xref>
<xref ref-type="bibr" rid="bibr72-0897190011431631"/>
<xref ref-type="bibr" rid="bibr73-0897190011431631"/>–<xref ref-type="bibr" rid="bibr74-0897190011431631">74</xref>
</sup> However, in many of these trials the risk of thromboembolism was found when patients had hemoglobin levels &gt;12 g/dL or obtained an increase of &gt;1 g/dL in 14 days.<sup>
<xref ref-type="bibr" rid="bibr74-0897190011431631">74</xref>
</sup> Also, the cause of the venous thromboembolism is complex and may be related to the malignancy itself or the chemotherapy.<sup>
<xref ref-type="bibr" rid="bibr75-0897190011431631">75</xref>
<xref ref-type="bibr" rid="bibr76-0897190011431631"/>–<xref ref-type="bibr" rid="bibr77-0897190011431631">77</xref>
</sup>
</p>
<p>ESA therapy should only be used to treat chemotherapy-induced anemia and should be discontinued once the chemotherapy course is complete. Thus, treatment in patients not receiving concomitant myelosuppressive chemotherapy is not appropriate.<sup>
<xref ref-type="bibr" rid="bibr60-0897190011431631">60</xref>,<xref ref-type="bibr" rid="bibr61-0897190011431631">61</xref>
</sup> To minimize the risk of serious adverse events, practitioners should use the lowest dose possible needed to avoid RBC transfusions. Since these agents may promote tumor growth, they should only be used if the cancer is not curable. If the anticipated treatment outcome is cure, ESA therapy should not be used. For patients undergoing palliative treatment, ESA therapy is usually preferred over transfusion.</p>
<p>In order to prescribe ESA therapy to patients with anemia due to myelosuppressive chemotherapy, physicians and hospitals must enroll in and comply with the regulations of the ESA APPRISE Oncology Program. To enroll, visit www.esa-apprise.com. Additionally, prior to each subsequent course of ESA therapy, prescribers and patients must provide written acknowledgment of a discussion of all potential risks.</p>
<p>Recommended initial doses as well as alternative doses are listed in <xref ref-type="table" rid="table5-0897190011431631">Table 5</xref>. Response to ESA therapy must be assessed to determine whether the initial dose should be reduced, increased, or withheld. Keeping in mind that ESAs require at least 2 weeks of treatment before hemoglobin levels begin to rise and that the goal is a gradual increase in hemoglobin levels to avoid transfusions. Hemoglobin levels should be measured weekly until stable and dose adjustments should be made according to the recommendations in <xref ref-type="table" rid="table6-0897190011431631">Table 6</xref>. However, it should be noted that individual titrations may be needed.<sup>
<xref ref-type="bibr" rid="bibr51-0897190011431631">51</xref>
</sup>
</p>
<table-wrap id="table5-0897190011431631" position="float">
<label>Table 5.</label>
<caption>
<p>Initial Doses of ESA Therapy for Adult Patients Receiving Concomitant Myelosuppressive Chemotherapy<sup>
<xref ref-type="bibr" rid="bibr51-0897190011431631">51</xref>
</sup>
</p>
</caption>
<graphic alternate-form-of="table5-0897190011431631" xlink:href="10.1177_0897190011431631-table5.tif"/>
<table>
<thead>
<tr>
<th>Epoetin alfa (Procrit)</th>
<th>Darbepoetin alfa (Aranesp)  </th>
</tr>
</thead>
<tbody>
<tr>
<td>150 units/kg SC three times weekly<sup>
<xref ref-type="table-fn" rid="table-fn4-0897190011431631">a</xref>
</sup>
</td>
<td>2.25 mcg/kg SC once weekly<sup>
<xref ref-type="table-fn" rid="table-fn4-0897190011431631">a</xref>
</sup>
</td>
</tr>
<tr>
<td>40 000 units SC once weekly<sup>
<xref ref-type="table-fn" rid="table-fn4-0897190011431631">a</xref>
</sup>
</td>
<td>500 mcg SC every three weeks<sup>
<xref ref-type="table-fn" rid="table-fn4-0897190011431631">a</xref>
</sup> </td>
</tr>
<tr>
<td>80 000 units SC every 2 weeks</td>
<td>100 mcg SC once weekly</td>
</tr>
<tr>
<td>120 000 units SC every 3 weeks</td>
<td>200 mcg SC every 2 weeks</td>
</tr>
<tr>
<td>
</td>
<td>300 mcg SC every 3 weeks </td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0897190011431631">
<p>Abbreviations: ESA, erythropoietin-stimulating agent; SC, sucutaneously.</p>
</fn>
<fn id="table-fn4-0897190011431631">
<p>
<sup>a</sup> Recommended.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table6-0897190011431631" position="float">
<label>Table 6.</label>
<caption>
<p>Responses to ESA Therapy and Recommended Subsequent Actions<sup>
<xref ref-type="bibr" rid="bibr51-0897190011431631">51</xref>
</sup>
</p>
</caption>
<graphic alternate-form-of="table6-0897190011431631" xlink:href="10.1177_0897190011431631-table6.tif"/>
<table>
<thead>
<tr>
<th>Response</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin level increases by ≥1 g/dL during a 2-week period </td>
<td>Decrease dose by 25%-40%</td>
</tr>
<tr>
<td>Hemoglobin level rises to a level sufficient enough to avoid transfusion </td>
<td>Decrease dose by 25%-40%</td>
</tr>
<tr>
<td>No response (&lt;1 g/dL increase in hemoglobin) after 4 weeks of epoetin alfa or 6 weeks of darbepoetin alfa treatment </td>
<td>Increase dose by 50% </td>
</tr>
<tr>
<td>No response despite addition of iron supplementation after 8 or 9 weeks of therapy </td>
<td>Discontinue ESA therapy and consider PRBC transfusion</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0897190011431631">
<p>Abbreviations: ESA, erythropoietin-stimulating agent; PRBC, packed red blood cell.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section18-0897190011431631">
<title>Iron Supplementation</title>
<p>Iron deficiency often arises with continued ESA use. Monitoring of iron levels including serum iron, total iron-binding capacity, and serum ferritin should accompany ESA treatment. Iron supplementation will be required in most patients and may also improve response to ESA therapy. <sup>
<xref ref-type="bibr" rid="bibr78-0897190011431631">78</xref>,<xref ref-type="bibr" rid="bibr79-0897190011431631">79</xref>
</sup> Iron can be administered via oral or parenteral form and is available in low-molecular-weight iron dextran, ferric gluconate, and iron sucrose. Evidence from multiple published studies suggests that IV iron is superior to oral iron.<sup>
<xref ref-type="bibr" rid="bibr80-0897190011431631">80</xref>
<xref ref-type="bibr" rid="bibr81-0897190011431631"/>
<xref ref-type="bibr" rid="bibr82-0897190011431631"/>
<xref ref-type="bibr" rid="bibr83-0897190011431631"/>–<xref ref-type="bibr" rid="bibr84-0897190011431631">84</xref>
</sup> However, evidence from the largest trial to date challenged these results and found that IV iron failed to confer any benefit in terms of hemoglobin response, transfusion rates, or quality of life yet was associated with significantly more adverse events compared to oral iron and placebo.<sup>
<xref ref-type="bibr" rid="bibr85-0897190011431631">85</xref>
</sup> Adverse effects of parenteral iron include hypotension or hypertension, nausea, vomiting, diarrhea, pain, dyspnea, pruritis, headache, and dizziness.<sup>
<xref ref-type="bibr" rid="bibr86-0897190011431631">86</xref>,</sup>
<sup>
<xref ref-type="bibr" rid="bibr87-0897190011431631">87</xref>
</sup> Iron supplementation in general is also associated with increased risk for bacterial infection, thus it is not recommended for patients with active infection.<sup>
<xref ref-type="bibr" rid="bibr88-0897190011431631">88</xref>
</sup> Recommendations for iron supplementation in patients with cancer can be found in <xref ref-type="table" rid="table7-0897190011431631">Table 7</xref>.</p>
<table-wrap id="table7-0897190011431631" position="float">
<label>Table 7.</label>
<caption>
<p>General Recommendations for Iron Supplementation in Cancer Patients<sup>
<xref ref-type="bibr" rid="bibr51-0897190011431631">51</xref>
</sup>
</p>
</caption>
<graphic alternate-form-of="table7-0897190011431631" xlink:href="10.1177_0897190011431631-table7.tif"/>
<table>
<thead>
<tr>
<th>Recommendations for Iron Supplementation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. IV iron products are recommended over oral iron products.</td>
</tr>
<tr>
<td>2. Supplementation should be provided to cancer patients with absolute iron deficiency (ferritin &lt;30 ng/mL and transferrin saturation &lt;15%).</td>
</tr>
<tr>
<td>3. Supplementation should be considered in combination with ESA therapy in patients with functional iron deficiency (ferritin ≤800 ng/mL and transferrin saturation &lt;20%).</td>
</tr>
<tr>
<td>4. Most adverse events were associated with high-molecular-weight iron dextran (Dexferrum)<sup>
<xref ref-type="bibr" rid="bibr89-0897190011431631">89</xref>
</sup> and so the recommended iron dextran product is low-molecular-weight iron dextran (INFed).<sup>
<xref ref-type="bibr" rid="bibr90-0897190011431631">90</xref>
</sup>
</td>
</tr>
<tr>
<td>5. Test doses are required for iron dextran and are strongly suggested for ferric gluconate or iron sucrose in patients who are sensitive to iron dextran or have other drug allergies.</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-0897190011431631">
<p>Abbreviations: ESA, erythropoietin-stimulating agent; IV, intravenous.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="section19-0897190011431631">
<title>Neutropenia</title>
<p>Neutropenia (defined as &lt;500 neutrophils/mL or &lt;1000 neutrophils/mL and predicted to decline to ≤500 in the next 48 hours) and resulting febrile neutropenia (FN) is a major dose-limiting toxicity of myelosuppressive chemotherapy. It is estimated that about 25% to 40% of treatment-naive patients develop FN with common chemotherapy regimens. Neutropenia frequently results in the use of broad-spectrum antibiotics, longer hospital stays, and higher treatment costs.<sup>
<xref ref-type="bibr" rid="bibr91-0897190011431631">91</xref>
</sup> Patients who develop neutropenia often require chemotherapy dose reductions or delays in subsequent treatment cycles, which can result in compromised clinical outcomes. Additionally, neutropenia has also been associated with decreased quality of life as measured by physical functioning, vitality, and mental health.<sup>
<xref ref-type="bibr" rid="bibr6-0897190011431631">6</xref>
</sup>
</p>
<sec id="section20-0897190011431631">
<title>Risk Assessment</title>
<p>When determining appropriate candidates for prophylactic use of myeloid growth factors (granulocyte colony-stimulating factors [G-CSFs]), health care providers should perform an evaluation of chemotherapy-induced FN prior to the first cycle. Increased age (over 65) is the most important risk factor for developing severe neutropenia.<sup>
<xref ref-type="bibr" rid="bibr92-0897190011431631">92</xref>
<xref ref-type="bibr" rid="bibr93-0897190011431631"/>
<xref ref-type="bibr" rid="bibr94-0897190011431631"/>–<xref ref-type="bibr" rid="bibr95-0897190011431631">95</xref>
</sup> Other risk factors include previous chemotherapy or radiation, preexisting neutropenia or infection, tumor involvement in the bone marrow, poor performance status, and renal or liver dysfunction.<sup>
<xref ref-type="bibr" rid="bibr96-0897190011431631">96</xref>
</sup> The type of cancer, myelosuppressive capacity and intensity of the chemotherapy, and treatment intent should also be considered.</p>
</sec>
<sec id="section21-0897190011431631">
<title>Who Should Receive G-CSFs?</title>
<p>Filgrastim and pegfilgrastim are G-CSFs approved for prevention of chemotherapy-induced neutropenia.<sup>
<xref ref-type="bibr" rid="bibr97-0897190011431631">97</xref>,<xref ref-type="bibr" rid="bibr98-0897190011431631">98</xref>
</sup> In contrast, sargramostim is a granulocyte macrophage colony-stimulating factor (GM-CSF) that is only indicated following chemotherapy for acute myeloid leukemia and for stem cell transplantations.<sup>
<xref ref-type="bibr" rid="bibr99-0897190011431631">99</xref>
</sup> Prophylactic use of G-CSFs is recommended for all patients at high risk of developing FN (≥20%), regardless of whether the treatment is intended to be curative, to prolong survival, or to manage symptoms and increase quality of life (guidelines). For patients at intermediate risk (10%-20%), use of G-CSFs should be considered on an individual basis after a risk–benefit discussion between the patient and the physician. Myeloid growth factors should generally not be used in patients at low risk</p>
<p>(&lt;10%) because it is not considered cost effective and alternative treatment options are available. However, it may be considered if the patient is at significant risk for serious medical consequences of FN, including death.<sup>
<xref ref-type="bibr" rid="bibr100-0897190011431631">100</xref>
<xref ref-type="bibr" rid="bibr101-0897190011431631"/>–<xref ref-type="bibr" rid="bibr102-0897190011431631">102</xref>
</sup>
</p>
</sec>
<sec id="section22-0897190011431631">
<title>Evaluation of Subsequent Chemotherapy Cycles</title>
<p>Patient evaluation should be performed prior to each subsequent cycle of chemotherapy to determine the treatment intent and risk of FN. If the patient experienced an episode of FN or a dose-limiting consequence of neutropenia during the previous cycle, they are now considered in the high-risk group. If the patient develops FN despite receiving prophylactic G-CSF, either the dose of chemotherapy should be reduced or the treatment regimen changed, unless there is an impact on survival.<sup>
<xref ref-type="bibr" rid="bibr96-0897190011431631">96</xref>
</sup>
</p>
</sec>
<sec id="section23-0897190011431631">
<title>G-CSF Benefits and Risks</title>
<p>Selective use of myeloid growth factors in patients at increased risk for neutropenia has been shown to reduce the incidence, length, and severity of chemotherapy-induced neutropenia.<sup>
<xref ref-type="bibr" rid="bibr103-0897190011431631">103</xref>
<xref ref-type="bibr" rid="bibr104-0897190011431631"/>
<xref ref-type="bibr" rid="bibr105-0897190011431631"/>–<xref ref-type="bibr" rid="bibr106-0897190011431631">106</xref>
</sup> They also may enhance the cost-effectiveness and increase the likelihood of delivery of full-dose chemotherapy at the planned schedule.<sup>
<xref ref-type="bibr" rid="bibr103-0897190011431631">103</xref>
</sup>
<sup>,<xref ref-type="bibr" rid="bibr106-0897190011431631">106</xref>
<xref ref-type="bibr" rid="bibr107-0897190011431631"/>–<xref ref-type="bibr" rid="bibr108-0897190011431631">108</xref> </sup>Additionally, a recent systematic review has shown that prophylactic use of G-CSF agents can substantially reduce the risk of infection-related mortality.<sup>
<xref ref-type="bibr" rid="bibr109-0897190011431631">109</xref>
</sup>
</p>
<p>G-CSFs are generally well tolerated. Common side effects include flu-like symptoms, injection site reaction, and bone pain. Warnings on myeloid growth factors include allergic reactions, splenic rupture, acute respiratory distress syndrome, and sickle cell disease crisis.<sup>
<xref ref-type="bibr" rid="bibr97-0897190011431631">97</xref>,<xref ref-type="bibr" rid="bibr98-0897190011431631">98</xref>
</sup>
</p>
</sec>
<sec id="section24-0897190011431631">
<title>Dosing and Administration</title>
<p>Administration of G-CSF should take place 24 to 72 hours after chemotherapy is completed. Same day administration (within 24 hours of chemotherapy) is not recommended. Filgrastim is dosed at 5 mcg/kg SQ daily until the absolute neutrophil count (ANC) levels are normal or near normal. One dose of pegfilgrastim 6 mg SQ should be given per treatment cycle.<sup>
<xref ref-type="bibr" rid="bibr96-0897190011431631">96</xref>
</sup> There is evidence to support the use of pegfilgrastim with chemotherapy cycles given every 3 or every 2 weeks; however, there is insufficient evidence for weekly regimens.<sup>
<xref ref-type="bibr" rid="bibr104-0897190011431631">104</xref>,<xref ref-type="bibr" rid="bibr110-0897190011431631">110</xref>
</sup>
</p>
</sec>
<sec id="section25-0897190011431631">
<title>Treatment with G-CSF</title>
<p>There is less evidence displaying the benefits of therapeutic use of G-CSF compared to prophylactic use. Myeloid growth factors should definitely not be used for treatment in afebrile neutropenic patients. If the patient develops FN, they should be treated with antibiotics. The use of G-CSF along with antibiotics can be considered based on patient risk factors including increased age (&gt;65), sepsis, expected prolonged (&gt;10 days) and severe neutropenia (ANC &lt;100/mL), pneumonia, invasive fungal infection, hospitalization, and prior episode of FN.<sup>
<xref ref-type="bibr" rid="bibr96-0897190011431631">96</xref>
</sup> If therapeutic G-CSF is deemed appropriate, patients should only be treated with filgrastim since there is a lack of evidence for treatment with pegfilgrastim. Additionally, if a patient has received prophylactic pegfilgrastrim, they should not be treated with an additional G-CSF, since pegfilrgastim is long acting.<sup>
<xref ref-type="bibr" rid="bibr111-0897190011431631">111</xref>
</sup>
</p>
</sec>
</sec>
<sec id="section26-0897190011431631">
<title>Pharmacist’s Role</title>
<p>Upon diagnosis of cancer, patients often experience a myriad of feelings including fear, sadness, anger, and confusion. Questions may be raised such as what will my course of treatment be? Will I lose my hair? Will I be vomiting all day long? Will my pain be unbearable? Will I be able to live a normal life with friends and family or will I be lying in a hospital bed alone? And will I die from this disease? Being diagnosed with cancer is frightening enough and undergoing chemotherapy usually only adds more stress, fear, and anxiety. This is where the pharmacist can play an important role in impacting the quality of life that these patients live.</p>
<p>Pharmacists can provide detailed instructions and information on how to take complicated medication regimens such as oral chemotherapy, antiemetics and pain medication. We can also play a significant role in adverse drug effect monitoring by assisting patients with cancer in implementing adverse drug event monitoring plans. Patient’s self-documented symptoms can be valuable data used to help tailor medication regimens and improve clinical status.<sup>
<xref ref-type="bibr" rid="bibr112-0897190011431631">112</xref>
</sup> Medication adherence is another area in which pharmacists can have a positive impact. Since chemotherapy often has terrible adverse effects, adherence to these medications can be difficult for some patients. Pharmacists can help improve medication adherence by providing information, reminders, reinforcement, counseling, telephone follow-ups, and assisting with self-monitoring.<sup>
<xref ref-type="bibr" rid="bibr113-0897190011431631">113</xref>
</sup> Finally, pharmacists can help evaluate the appropriateness of chemotherapy and supportive care regimens and provide physician recommendations for adjustments in treatment. A recent study demonstrated that the use of a pharmacist-led interdisciplinary team produced and maintained an improvement in symptom scores in patients receiving oncology services including gynecologic, radiation, medical, and surgical. Therefore, it is possible that shortages among oncology providers may be mitigated by pharmacists working in collaborative practice agreements with prescriptive authority in the ambulatory care and inpatient oncology setting.<sup>
<xref ref-type="bibr" rid="bibr114-0897190011431631">114</xref>
</sup>
</p>
<p>Regardless of the practice setting, pharmacists can play a vital role in supportive care management of patients with cancer. They can significantly help reduce treatment and cancer-related adverse effects such as chemotherapy-induced nausea and vomiting, pain, anemia, and neutropenia.<sup>
<xref ref-type="bibr" rid="bibr115-0897190011431631">115</xref> </sup>From the first day of diagnosis through the last cycle of treatment, pharmacists can use their knowledgeable and caring expertise to help patients with cancer live the longest and best quality of life possible.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-0897190011431631">
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0897190011431631">
<p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0897190011431631">
<label>1</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Altekruse</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Kosary</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Krapcho</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <source>SEER Cancer Statistics Review, 1975-2007</source>. <publisher-loc>Bethesda, MD</publisher-loc>: <publisher-name>National Cancer Institute</publisher-name>. <comment>[Online]. 2010. [cited 2011 Jun 13]</comment>. <ext-link ext-link-type="uri" xlink:href="http://seer.cancer.gov/csr/1975_2007/">http://seer.cancer.gov/csr/1975_2007/</ext-link>.</citation>
</ref>
<ref id="bibr2-0897190011431631">
<label>2</label>
<citation citation-type="book">
<collab collab-type="author">American Cancer Society</collab>. <source>Cancer Facts and Figures 2010</source>. <comment>[Online]. 2010. [cited 2011 Jun 13]</comment>. <ext-link ext-link-type="uri" xlink:href="http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-and-figures-2010">http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-and-figures-2010</ext-link>.</citation>
</ref>
<ref id="bibr3-0897190011431631">
<label>3</label>
<citation citation-type="book">
<collab collab-type="author">American Cancer Society</collab>. <source>Treatments and Side Effects</source>. <comment>[Online]. 2011. [cited 2011 Jun 13]</comment>. <ext-link ext-link-type="uri" xlink:href="http://www.cancer.org/Treatment/TreatmentsandSideEffects/index">http://www.cancer.org/Treatment/TreatmentsandSideEffects/index</ext-link>.</citation>
</ref>
<ref id="bibr4-0897190011431631">
<label>4</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Laszlo</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Emesis as limiting toxicity in cancer chemotherapy</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Laszlo</surname>
<given-names>J</given-names>
</name>
</person-group>, ed. <source>Antiemetics and Cancer Chemotherapy</source>. <publisher-loc>Baltimore, Maryland</publisher-loc>: <publisher-name>Williams &amp; Wilkins</publisher-name>; <year>1983</year>:<fpage>1</fpage>–<lpage>5</lpage>.</citation>
</ref>
<ref id="bibr5-0897190011431631">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Richardson</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Marks</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Levine</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy</article-title>. <source>J Clin Oncol</source>. <year>1988</year>;<volume>6</volume>:<fpage>1746</fpage>–<lpage>1752</lpage>.</citation>
</ref>
<ref id="bibr6-0897190011431631">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fortner</surname>
<given-names>BV</given-names>
</name>
<name>
<surname>Schwartzberg</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Tauer</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Impact of chemotherapy induced neutropenia on quality of life: a prospective pilot investigation</article-title>. <source>Support Care Cancer</source>. <year>2005</year>;<volume>13</volume>:<fpage>522</fpage>–<lpage>528</lpage>.</citation>
</ref>
<ref id="bibr7-0897190011431631">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bates</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Spell</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Cullen</surname>
<given-names>DJ</given-names>
</name>
<etal/>
</person-group>. <article-title>The costs of adverse drug events in hospitalized patients</article-title>. <source>JAMA</source>. <year>1997</year>;<volume>277</volume>(<issue>4</issue>):<fpage>307</fpage>–<lpage>311</lpage>.</citation>
</ref>
<ref id="bibr8-0897190011431631">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hesketh</surname>
<given-names>PJ</given-names>
</name>
</person-group>. <article-title>Chemotherapy-Induced Nausea and Vomiting</article-title>. <source>N Engl J Med</source>. <year>2008</year>;<volume>358</volume>:<fpage>2482</fpage>–<lpage>2494</lpage>.</citation>
</ref>
<ref id="bibr9-0897190011431631">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Boer-Dennert</surname>
<given-names>M</given-names>
</name>
<name>
<surname>de Wit</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Schmitz</surname>
<given-names>PI</given-names>
</name>
<etal/>
</person-group>. <article-title>Patient perceptions of the side effects of chemotherapy: the influence of 5HT3 antagonists</article-title>. <source>Br J Cancer</source>. <year>1997</year>;<volume>76</volume>:<fpage>1055</fpage>–<lpage>1061</lpage>.</citation>
</ref>
<ref id="bibr10-0897190011431631">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hickok</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Roscoe</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Morrow</surname>
<given-names>GR</given-names>
</name>
<etal/>
</person-group>. <article-title>Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a Universityof Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community</article-title>. <source>Cancer</source>. <year>2003</year>;<volume>97</volume>:<fpage>2880</fpage>–<lpage>2886</lpage>.</citation>
</ref>
<ref id="bibr11-0897190011431631">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitchell</surname>
<given-names>EP</given-names>
</name>
</person-group>. <article-title>Gastrointestinal toxicity of chemotherapeutic agents</article-title>. <source>Semin Oncol</source>. <year>1992</year>;<volume>19</volume>:<fpage>566</fpage>–<lpage>579</lpage>.</citation>
</ref>
<ref id="bibr12-0897190011431631">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roila</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Herrstedt</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Aapro</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Guideline update for MASCC and ESMO in the prevention of chemotherapy and radiotherapy induced nausea and vomiting: results of the Perugia consensus conference</article-title>. <source>Ann Oncol</source>. <year>2010</year>;<volume>21</volume>(<issue>suppl 5</issue>):<fpage>v232</fpage>–<lpage>v243</lpage>.</citation>
</ref>
<ref id="bibr13-0897190011431631">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grunberg</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Warr</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Gralla</surname>
<given-names>RJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity state of the art</article-title>. <source>Support Care Cancer</source>. <year>2011</year>;<volume>19</volume>(<issue>suppl 1</issue>):<fpage>S43</fpage>–<lpage>S47</lpage>.</citation>
</ref>
<ref id="bibr14-0897190011431631">
<label>14</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Ettinger</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Armstrong</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>MJ</given-names>
</name>
<etal/>
</person-group>. <source>National Comprehensive Cancer Network Antiemesis Guidelines. 2011 Version 3</source>. <comment>[Online]. [cited Jun 2 2011]</comment>. <ext-link ext-link-type="uri" xlink:href="http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf">http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf</ext-link>
</citation>
</ref>
<ref id="bibr15-0897190011431631">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Osoba</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zee</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Pater</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Determinants of postchemotherapy nausea and vomiting in patients with cancer</article-title>. <source>J Clin Oncol</source>. <year>1997</year>;<volume>15</volume>:<fpage>116</fpage>–<lpage>123</lpage>.</citation>
</ref>
<ref id="bibr16-0897190011431631">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roscoe</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Bushunnow</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Morrow</surname>
<given-names>GR</given-names>
</name>
<etal/>
</person-group>. <article-title>Patient experience is a strong predictor of severe nausea after chemotherapy: a University of Rochester Community Clinical Oncology Program study of patients with breast carcinoma</article-title>. <source>Cancer</source>. <year>2004</year>;<volume>101</volume>:<fpage>2701</fpage>–<lpage>2708</lpage>.</citation>
</ref>
<ref id="bibr17-0897190011431631">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tavorath</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hesketh</surname>
<given-names>PJ</given-names>
</name>
</person-group>. <article-title>Drug treatment of chemotherapy-induced delayed emesis</article-title>. <source>Drugs</source>. <year>1996</year>;<volume>52</volume>:<fpage>639</fpage>–<lpage>648</lpage>.</citation>
</ref>
<ref id="bibr18-0897190011431631">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kris</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Hesketh</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Somerfield</surname>
<given-names>MR</given-names>
</name>
<etal/>
</person-group>. <article-title>American Society of Clinical Oncology guidelines for antiemetics in oncology: update 2006</article-title>. <source>J Clin Oncol</source>. <year>2006</year>;<volume>24</volume>:<fpage>2932</fpage>–<lpage>2947</lpage>.</citation>
</ref>
<ref id="bibr19-0897190011431631">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roila</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hesketh</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Herrstedt</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Prevention of chemotherapy and radiotherapy induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference</article-title>. <source>Ann Oncol</source>. <year>2006</year>;<volume>17</volume>:<fpage>20</fpage>–<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr20-0897190011431631">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Massa</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Astara</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Madeddu</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Palonsetron plus dexamethasone effectively prevents acute and delayed chemotherapy induced nause and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response</article-title>. <source>Crit Rev Oncol Hematol</source>. <year>2009</year>;<volume>70</volume>:<fpage>83</fpage>–<lpage>91</lpage>.</citation>
</ref>
<ref id="bibr21-0897190011431631">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ezzo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Vickers</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Richardson</surname>
<given-names>MA</given-names>
</name>
<etal/>
</person-group>. <article-title>Acupuncture-point stimulation for chemotherapy induced nausea and vomiting</article-title>. <source>J Clin Oncol</source>. <year>2005</year>;<volume>23</volume>:<fpage>7188</fpage>–<lpage>7198</lpage>.</citation>
</ref>
<ref id="bibr22-0897190011431631">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morrow</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Morrell</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy</article-title>. <source>N Engl J Med</source>. <year>1982</year>;<volume>307</volume>:<fpage>1476</fpage>–<lpage>1480</lpage>.</citation>
</ref>
<ref id="bibr23-0897190011431631">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Figueroa-Moseley</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Jean-Pierre</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Roscoe</surname>
<given-names>JA</given-names>
</name>
<etal/>
</person-group>. <article-title>Behavioral interventions in treating anticipatory nausea and vomiting</article-title>. <source>J Natl Compr Canc Netw</source>. <year>2007</year>;<volume>5</volume>:<fpage>44</fpage>–<lpage>50</lpage>.</citation>
</ref>
<ref id="bibr24-0897190011431631">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Molassiotis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yung</surname>
<given-names>HP</given-names>
</name>
<name>
<surname>Yam</surname>
<given-names>BM</given-names>
</name>
<etal/>
</person-group>. <article-title>The effectiveness of progressive muscle relaxation training in managing chemotherapy induced nausea and vomiting in Chinese breast cancer patients: a randomized controlled trial</article-title>. <source>Support Care Cancer</source>. <year>2002</year>;<volume>10</volume>:<fpage>237</fpage>–<lpage>246</lpage>.</citation>
</ref>
<ref id="bibr25-0897190011431631">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Razavi</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Delvaux</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Farvacques</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam</article-title>. <source>J Clin Oncol</source>. <year>1993</year>;<volume>11</volume>:<fpage>1384</fpage>–<lpage>1390</lpage>.</citation>
</ref>
<ref id="bibr26-0897190011431631">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohen</surname>
<given-names>MZ</given-names>
</name>
<name>
<surname>Easley</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Ellis</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Cancer pain mangement and the JCAHO’s pain standards: an institutional challenge</article-title>. <source>J Pain Symptom Manage</source>. <year>2003</year>;<volume>25</volume>:<fpage>519</fpage>–<lpage>527</lpage>.</citation>
</ref>
<ref id="bibr27-0897190011431631">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Svendsen</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Andersen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Arnason</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms</article-title>. <source>Eur J Pain</source>. <year>2005</year>;<volume>9</volume>:<fpage>195</fpage>–<lpage>206</lpage>.</citation>
</ref>
<ref id="bibr28-0897190011431631">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cleeland</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Gonin</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hatfield</surname>
<given-names>AK</given-names>
</name>
<etal/>
</person-group>. <article-title>Pain and its treatment in outpatients with metastatic cancer</article-title>. <source>N Engl J Med</source>. <year>1994</year>;<volume>330</volume>:<fpage>592</fpage>–<lpage>596</lpage>.</citation>
</ref>
<ref id="bibr29-0897190011431631">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Serlin</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Mendoza</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function</article-title>. <source>Pain</source>. <year>1995</year>;<volume>61</volume>:<fpage>277</fpage>–<lpage>284</lpage>.</citation>
</ref>
<ref id="bibr30-0897190011431631">
<label>30</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Swarm</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Abemethy</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Anghelscu</surname>
<given-names>DL</given-names>
</name>
<etal/>
</person-group>. National Comprehensive Cancer Network Adult Cancer Pain Guidelines. 2011 Version 1. <comment>[Online]. [cited Jun 2 2011]</comment>. <ext-link ext-link-type="uri" xlink:href="http://www.nccn.org/professionals/physician_gls/pdf/pain.pdf">http://www.nccn.org/professionals/physician_gls/pdf/pain.pdf</ext-link>
</citation>
</ref>
<ref id="bibr31-0897190011431631">
<label>31</label>
<citation citation-type="journal">
<collab collab-type="author">Merskey H, Bogduk N. Classification of chronic pain</collab>. <article-title>Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain. Subcommittee on Taxonomy</article-title>. <source>Pain Suppl</source>. <year>1986</year>;<volume>3</volume>:<fpage>S1</fpage>–<lpage>226</lpage>.</citation>
</ref>
<ref id="bibr32-0897190011431631">
<label>32</label>
<citation citation-type="book">
<collab collab-type="author">United States Department of Health and Human Services. <italic>U.S.</italic> Food and Drug Administration</collab>. <comment>[Online]. 2010. [cited Jun 8 2011]</comment>. <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov">http://www.fda.gov</ext-link>.</citation>
</ref>
<ref id="bibr33-0897190011431631">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruera</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>HN</given-names>
</name>
</person-group>. <article-title>Cancer pain</article-title>. <source>JAMA</source>. <year>2003</year>;<volume>290</volume>:<fpage>2476</fpage>–<lpage>2479</lpage>.</citation>
</ref>
<ref id="bibr34-0897190011431631">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Portenoy</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Lesage</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Management of cancer pain</article-title>. <source>Lancet</source>. <year>1999</year>;<volume>353</volume>:<fpage>1695</fpage>–<lpage>1700</lpage>.</citation>
</ref>
<ref id="bibr35-0897190011431631">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stevens</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Ghazi</surname>
<given-names>SM</given-names>
</name>
</person-group>. <article-title>Routes of opioid analgesic therapy in the management of cancer pain</article-title>. <source>Cancer Control</source>. <year>2000</year>;<volume>7</volume>:<fpage>132</fpage>–<lpage>141</lpage>.</citation>
</ref>
<ref id="bibr36-0897190011431631">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harris</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Suresh Kumar</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Rajagopal</surname>
<given-names>MR</given-names>
</name>
</person-group>. <article-title>Intravenous morphine for rapid control of severe cancer pain</article-title>. <source>Palliat Med</source>. <year>2003</year>;<volume>17</volume>:<fpage>248</fpage>–<lpage>256</lpage>.</citation>
</ref>
<ref id="bibr37-0897190011431631">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cherny</surname>
<given-names>NI</given-names>
</name>
</person-group>. <article-title>The pharmacologic management of cancer pain</article-title>. <source>Oncology (Williston Park)</source>. <year>2004</year>;<volume>18</volume>:<fpage>1499</fpage>–<lpage>1515</lpage>.</citation>
</ref>
<ref id="bibr38-0897190011431631">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hanks</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>Conno</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cherny</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Morphine and alternative opioids in cancer pain: the EAPC recommendations</article-title>. <source>Br J Cancer</source>. <year>2001</year>;<volume>84</volume>:<fpage>587</fpage>–<lpage>593</lpage>.</citation>
</ref>
<ref id="bibr39-0897190011431631">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klepstad</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kaasa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Borchegrevink</surname>
<given-names>PC</given-names>
</name>
</person-group>. <article-title>Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine</article-title>. <source>Eur J Clin Pharmacol</source>. <year>2000</year>;<volume>55</volume>:<fpage>713</fpage>–<lpage>719</lpage>.</citation>
</ref>
<ref id="bibr40-0897190011431631">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tiseo</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Thaler</surname>
<given-names>HT</given-names>
</name>
<name>
<surname>Lapin</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Morphine-6-glucuronide concentrations and opioid related side effects: a survey in cancer patients</article-title>. <source>Pain</source>. <year>1995</year>;<volume>61</volume>:<fpage>47</fpage>–<lpage>54</lpage>.</citation>
</ref>
<ref id="bibr41-0897190011431631">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Portenoy</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Foley</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Stulman</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady state concentrations and the consequences of renal failure</article-title>. <source>Pain</source>. <year>1991</year>;<volume>47</volume>:<fpage>13</fpage>–<lpage>19</lpage>.</citation>
</ref>
<ref id="bibr42-0897190011431631">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manfredi</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Houde</surname>
<given-names>RW</given-names>
</name>
</person-group>. <article-title>Prescribing Methadone, a unique analgesic</article-title>. <source>J Support Oncol</source>. <year>2003</year>;<volume>1</volume>:<fpage>216</fpage>–<lpage>220</lpage>.</citation>
</ref>
<ref id="bibr43-0897190011431631">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McNicol</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Horowicz-Mehler</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Fisk</surname>
<given-names>RA</given-names>
</name>
<etal/>
</person-group>. <article-title>Management of opioid side effects in cancer related and chronic noncancer pain: a systematic review</article-title>. <source>J Pain</source>. <year>2003</year>;<volume>4</volume>:<fpage>231</fpage>–<lpage>256</lpage>.</citation>
</ref>
<ref id="bibr44-0897190011431631">
<label>44</label>
<citation citation-type="book">
<collab collab-type="author">American Pain Society</collab>. <source>Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain</source>. <edition>5th ed</edition>. <publisher-loc>Glenview, IL</publisher-loc>: <publisher-name>American Pain Society</publisher-name>; <year>2003</year>.</citation>
</ref>
<ref id="bibr45-0897190011431631">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manfredi</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Gonzales</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Sady</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Neuropathic pain in patients with cancer</article-title>. <source>J Palliat Care</source>. <year>2003</year>;<volume>19</volume>:<fpage>115</fpage>–<lpage>118</lpage>.</citation>
</ref>
<ref id="bibr46-0897190011431631">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Body</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Bartl</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Burckhardt</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Current use of bisphosphonates in oncology</article-title>. <source>J Clin Oncol</source>. <year>1998</year>;<volume>16</volume>:<fpage>3890</fpage>–<lpage>3899</lpage>.</citation>
</ref>
<ref id="bibr47-0897190011431631">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knight</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wade</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Balducci</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Prevalence and outcomes of anemia in cancer: a systematic review of the literature</article-title>. <source>Am J Med</source>. <year>2004</year>;<volume>116</volume>(<issue>suppl 7a</issue>):<fpage>11S</fpage>–<lpage>26S</lpage>.</citation>
</ref>
<ref id="bibr48-0897190011431631">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ludwig</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Van Belle</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Barrett-Lee</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anemia in cancer patients</article-title>. <source>Eur J Cancer</source>. <year>2004</year>;<volume>40</volume>:<fpage>2293</fpage>–<lpage>2306</lpage>.</citation>
</ref>
<ref id="bibr49-0897190011431631">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Groopman</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Itri</surname>
<given-names>LM</given-names>
</name>
</person-group>. <article-title>Chemotherapy-induced anemia in adults: incidence and treatment</article-title>. <source>J Natl Cancer Inst</source>. <year>1999</year>;<volume>91</volume>:<fpage>1616</fpage>–<lpage>1634</lpage>.</citation>
</ref>
<ref id="bibr50-0897190011431631">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Raferty</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbopoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment</article-title>. <source>Health Technol Assess</source>. <year>2007</year>;<volume>11</volume>:<fpage>1</fpage>–<lpage>202</lpage>.</citation>
</ref>
<ref id="bibr51-0897190011431631">
<label>51</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Rodgers</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Blinder</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. National Comprehensive Cancer Network Cancer and Chemotherapy Induced Anemia Guidelines. <year>2011</year> <comment>Version 2. [Online]. [cited Jun 2 2011]</comment>. <ext-link ext-link-type="uri" xlink:href="http://www.nccn.org/professionals/physician_gls/pdf/anemia.pdf">http://www.nccn.org/professionals/physician_gls/pdf/anemia.pdf</ext-link>
</citation>
</ref>
<ref id="bibr52-0897190011431631">
<label>52</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Quraishy</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bachowski</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Richard</surname>
<given-names>BJ</given-names>
</name>
<etal/>
</person-group>. <article-title>A Compendium of Transfusion Practice Guidelines</article-title>. <comment>American Red Cross. 2010 Version 1. [Online]</comment>. <ext-link ext-link-type="uri" xlink:href="http://www.redcrossblood.org/hospitals/educational-resources">http://www.redcrossblood.org/hospitals/educational-resources</ext-link>.</citation>
</ref>
<ref id="bibr53-0897190011431631">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wiesen</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Hospenthal</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Byrd</surname>
<given-names>JC</given-names>
</name>
<etal/>
</person-group>. <article-title>Equilibration of hemoglobin concentration after transfusion in medical inpatients actively bleeding</article-title>. <source>Ann Intern Med</source>. <year>1994</year>;<volume>121</volume>:<fpage>278</fpage>–<lpage>230</lpage>.</citation>
</ref>
<ref id="bibr54-0897190011431631">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kader</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Berthelet</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Prognostic significance of blood transfusions in patients with esophageal cancer treated with combined chemoradiotherapy</article-title>. <source>Am J Clin Oncol</source>. <year>2007</year>;<volume>30</volume>:<fpage>492</fpage>–<lpage>497</lpage>.</citation>
</ref>
<ref id="bibr55-0897190011431631">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spivak</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Gascon</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ludwig</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Anemia management in oncology and hematology</article-title>. <source>Oncologist</source>. <year>2009</year>;<volume>14</volume>(<issue>suppl 1</issue>):<fpage>43</fpage>–<lpage>56</lpage>.</citation>
</ref>
<ref id="bibr56-0897190011431631">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khorana</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Francis</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Blumberg</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer</article-title>. <source>Arch Intern Med</source>. <year>2008</year>;<volume>168</volume>:<fpage>2377</fpage>–<lpage>2381</lpage>.</citation>
</ref>
<ref id="bibr57-0897190011431631">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Littlewood</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Bajetta</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Nortier</surname>
<given-names>JW</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients recieving nonplatinum chemotherapy: results of a randomized, double blind, placebo controlled trial</article-title>. <source>J Clin Oncol</source>. <year>2001</year>;<volume>19</volume>:<fpage>2865</fpage>–<lpage>2874</lpage>.</citation>
</ref>
<ref id="bibr58-0897190011431631">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vansteenkiste</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pirker</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Massuti</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Double-blind, placebo controlled randomized phase III trial of darbopoetin alfa in lung cancer patients receiving chemotherapy</article-title>. <source>J Natl Cancer Inst</source>. <year>2002</year>;<volume>94</volume>:<fpage>1211</fpage>–<lpage>1220</lpage>.</citation>
</ref>
<ref id="bibr59-0897190011431631">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bohilus</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Seidenfeld</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients</article-title>. <source>J Natl Cancer Inst</source>. <year>2006</year>;<volume>98</volume>:<fpage>708</fpage>–<lpage>714</lpage>.</citation>
</ref>
<ref id="bibr60-0897190011431631">
<label>60</label>
<citation citation-type="book">
<collab collab-type="author">National Institutes of Health</collab>. <source>Epoetin alfa label</source>. <comment>[Online]. [cited Jun 8 2011]</comment>. <ext-link ext-link-type="uri" xlink:href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=15676">http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=15676</ext-link>
</citation>
</ref>
<ref id="bibr61-0897190011431631">
<label>61</label>
<citation citation-type="book">
<collab collab-type="author">National Institutes of Health</collab>. <source>Darbepoetin alfa label</source>. <comment>[Online]. [cited Jun 8 2011]</comment>. <ext-link ext-link-type="uri" xlink:href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=39953">http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=39953</ext-link>
</citation>
</ref>
<ref id="bibr62-0897190011431631">
<label>62</label>
<citation citation-type="book">F<collab collab-type="author">ood and Drug Administration</collab>. Press release: FDA receives new data on risks of anemia drugs consistent with previous data on tumor growth and death. <comment>2008 [Online]. [cited Jun 8 2011]</comment>. <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116830.htm">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116830.htm</ext-link>
</citation>
</ref>
<ref id="bibr63-0897190011431631">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hedenus</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Adriansson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>San Miguel</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind placebo-controlled study</article-title>. <source>J Haematol</source>. <year>2003</year>;<volume>122</volume>:<fpage>394</fpage>–<lpage>403</lpage>.</citation>
</ref>
<ref id="bibr64-0897190011431631">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Henke</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Laszig</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rube</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial</article-title>. <source>Lancet</source>. <year>2003</year>;<volume>362</volume>:<fpage>1255</fpage>–<lpage>1260</lpage>.</citation>
</ref>
<ref id="bibr65-0897190011431631">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leyland-Jones</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Semiglazov</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Pawlicki</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Maintaining normal hemoglobina levels with epoetin alfa in mainly nonanemic patients with metastic breast cancer receiving first-line chemotherapy: a survival study</article-title>. <source>J Clin Oncol</source>. <year>2005</year>;<volume>23</volume>:<fpage>5960</fpage>–<lpage>5972</lpage>.</citation>
</ref>
<ref id="bibr66-0897190011431631">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>RE</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Aapro</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Ludwig</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study</article-title>. <source>J Clin Oncol</source>. <year>2008</year>;<volume>26</volume>:<fpage>1040</fpage>–<lpage>1050</lpage>.</citation>
</ref>
<ref id="bibr67-0897190011431631">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomas</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hoebers</surname>
<given-names>FJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer</article-title>. <source>Gynecol Oncol</source>. <year>2008</year>;<volume>108</volume>:<fpage>317</fpage>–<lpage>325</lpage>.</citation>
</ref>
<ref id="bibr68-0897190011431631">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wright</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Ung</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Julian</surname>
<given-names>JA</given-names>
</name>
<etal/>
</person-group>. <article-title>Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small cell lung cancer with disease related anemia</article-title>. <source>J Clin Oncol</source>. <year>2007</year>;<volume>25</volume>:<fpage>1027</fpage>–<lpage>1032</lpage>.</citation>
</ref>
<ref id="bibr69-0897190011431631">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bennett</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Silver</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Djulbegovic</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia</article-title>. <source>JAMA</source>. <year>2008</year>;<volume>299</volume>:<fpage>914</fpage>–<lpage>924</lpage>.</citation>
</ref>
<ref id="bibr70-0897190011431631">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bohilius</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schmidlin</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Brillant</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomized trials</article-title>. <source>Lancet</source>. <year>2009</year>;<volume>373</volume>:<fpage>1532</fpage>–<lpage>1542</lpage>.</citation>
</ref>
<ref id="bibr71-0897190011431631">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tonelli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hemmelgarn</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Reiman</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis</article-title>. <source>CMAJ</source>. <year>2009</year>;<volume>180</volume>:<fpage>E62</fpage>–<lpage>E71</lpage>.</citation>
</ref>
<ref id="bibr72-0897190011431631">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ludwig</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Osterborg</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy induced anemia</article-title>. <source>J Clin Oncol</source>. <year>2009</year>;<volume>27</volume>:<fpage>2838</fpage>–<lpage>2847</lpage>.</citation>
</ref>
<ref id="bibr73-0897190011431631">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Glaspy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Vansteenkiste</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Erythropoiesis stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes</article-title>. <source>Br J Cancer</source>. <year>2010</year>;<volume>102</volume>:<fpage>301</fpage>–<lpage>315</lpage>.</citation>
</ref>
<ref id="bibr74-0897190011431631">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Glaspy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Osterborg</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ludwig</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Evaluation of the association between hemoglobin events and safety outcomes in cancer patients with chemotherapy induced anemia: an integrated analysis of patient-level data from 6 randomized, placebo-controlled trials of darbepoetin</article-title>. <source>Eur J Cancer Suppl</source>. <year>2007</year>;<volume>5</volume>:<comment>Abstract 147</comment>.</citation>
</ref>
<ref id="bibr75-0897190011431631">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heit</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Silverstein</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Mohr</surname>
<given-names>DN</given-names>
</name>
<etal/>
</person-group>. <article-title>Risk factors for deep vein thrombosis and pulmonary embolism: a population based case-ctronol study</article-title>. <source>Arch Intern Med</source>. <year>2000</year>;<volume>160</volume>:<fpage>809</fpage>–<lpage>815</lpage>.</citation>
</ref>
<ref id="bibr76-0897190011431631">
<label>76</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khorana</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Francis</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Culakova</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Thromboembolism is a leading cause of death in cancer patients recieving outpatient chemotherapy</article-title>. <source>J Thromb Haemost</source>. <year>2007</year>;<volume>5</volume>:<fpage>632</fpage>–<lpage>634</lpage>.</citation>
</ref>
<ref id="bibr77-0897190011431631">
<label>77</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levine</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Gent</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hirsh</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer</article-title>. <source>N Engl J Med</source>. <year>1988</year>;<volume>318</volume>:<fpage>404</fpage>–<lpage>407</lpage>.</citation>
</ref>
<ref id="bibr78-0897190011431631">
<label>78</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Henry</surname>
<given-names>DH</given-names>
</name>
</person-group>. <article-title>Supplemental iron: a key to optimizing the response of cancer-related anemia to rHuEPO?</article-title> <source>Oncologist</source>. <year>1998</year>;<volume>3</volume>:<fpage>275</fpage>–<lpage>278</lpage>.</citation>
</ref>
<ref id="bibr79-0897190011431631">
<label>79</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weiss</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Goodnough</surname>
<given-names>LT</given-names>
</name>
</person-group>. <article-title>Anemia of chronic disease</article-title>. <source>N Engl J Med</source>. <year>2005</year>;<volume>352</volume>:<fpage>1011</fpage>–<lpage>1023</lpage>.</citation>
</ref>
<ref id="bibr80-0897190011431631">
<label>80</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Auerbach</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ballard</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Trout</surname>
<given-names>JR</given-names>
</name>
<etal/>
</person-group>. <article-title>Intravenous iron optimizes response to recombinant human erythropoietin in cancer patients with chemotherapy related anemia: a multicenter, open-label, randomized trial</article-title>. <source>J Clin Oncol</source>. <year>2004</year>;<volume>22</volume>:<fpage>1301</fpage>–<lpage>1307</lpage>.</citation>
</ref>
<ref id="bibr81-0897190011431631">
<label>81</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Henry</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Dahl</surname>
<given-names>NV</given-names>
</name>
<name>
<surname>Auerbach</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy</article-title>. <source>Oncologist</source>. <year>2007</year>;<volume>12</volume>:<fpage>231</fpage>–<lpage>242</lpage>.</citation>
</ref>
<ref id="bibr82-0897190011431631">
<label>82</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hedenus</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Birgegard</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Nasman</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemia patients with lymphoproliferative malignancies: a randomized multicenter study</article-title>. <source>Leukemia</source>. <year>2007</year>;<volume>21</volume>:<fpage>627</fpage>–<lpage>632</lpage>.</citation>
</ref>
<ref id="bibr83-0897190011431631">
<label>83</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bastit</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Vanderbroek</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Altintas</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy induced anemia</article-title>. <source>J Clin Oncol</source>. <year>2008</year>;<volume>26</volume>:<fpage>1611</fpage>–<lpage>1618</lpage>.</citation>
</ref>
<ref id="bibr84-0897190011431631">
<label>84</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pedrazzoli</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Farris</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Del Prete</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Randomized trial of intravenous iron supplementation in patients with chemotherapy related anemia without iron deficiency treated with darbepoetin alpha</article-title>. <source>J Clin Oncol</source>. <year>2008</year>;<volume>26</volume>:<fpage>1619</fpage>–<lpage>1625</lpage>.</citation>
</ref>
<ref id="bibr85-0897190011431631">
<label>85</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steensma</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Dakhil</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Dalton</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>A phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy associated anemia: a study of the Mayo Clinic Cancer Research Consortium</article-title>. <source>ASH Annual Meeting</source>. <comment>Abstracts</comment> <year>2009</year>;<volume>114</volume>:<fpage>630</fpage>.</citation>
</ref>
<ref id="bibr86-0897190011431631">
<label>86</label>
<citation citation-type="book">
<collab collab-type="author">National Institutes of Health</collab>. Ferrlecit [package insert]. <comment>[Online]. 2010. [cited Jun 8 2011]</comment>. Bethesda, MD: US National Library of Medicine Publisher location. <ext-link ext-link-type="uri" xlink:href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=14265">http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=14265</ext-link>
</citation>
</ref>
<ref id="bibr87-0897190011431631">
<label>87</label>
<citation citation-type="book">
<collab collab-type="author">National Institutes of Health</collab>. Venofer [package insert]. <comment>[Online]. 2010. [cited Jun 8 2011].</comment> Bethesda, MD: US National Library of Medicine Publisher location. <ext-link ext-link-type="uri" xlink:href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=37706">http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=37706</ext-link>
</citation>
</ref>
<ref id="bibr88-0897190011431631">
<label>88</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lapointe</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Iron supplementation in the intensive care unit: when, how much, and by what route?</article-title> <source>Crit Care</source>. <year>2004</year>;<volume>8</volume>(<issue>suppl 2</issue>):<fpage>S37</fpage>–<lpage>S41</lpage>.</citation>
</ref>
<ref id="bibr89-0897190011431631">
<label>89</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chertow</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Mason</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Vaage-Nilsen</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Ahlem</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Update on adverse drug events associated with parenteral iron</article-title>. <source>Nephrol Dial Transplant</source>. <year>2006</year>;<volume>21</volume>:<fpage>378</fpage>–<lpage>382</lpage>.</citation>
</ref>
<ref id="bibr90-0897190011431631">
<label>90</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Auerbach</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ballard</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Glaspy</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Clinical update: intravenous iron for anaemia</article-title>. <source>Lancet</source>. <year>2007</year>;<volume>369</volume>:<fpage>1502</fpage>–<lpage>1504</lpage>.</citation>
</ref>
<ref id="bibr91-0897190011431631">
<label>91</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lyman</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Kuderer</surname>
<given-names>NM</given-names>
</name>
</person-group>. <article-title>Epidemiology of febrile neutropenia</article-title>. <source>Support Cancer Ther</source>. <year>2003</year>;<volume>1</volume>:<fpage>23</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr92-0897190011431631">
<label>92</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chrischilles</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Delgado</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Stolshek</surname>
<given-names>BS</given-names>
</name>
<etal/>
</person-group>. <article-title>Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin’s lymphoma</article-title>. <source>Cancer Control</source>. <year>2002</year>;<volume>9</volume>:<fpage>203</fpage>–<lpage>211</lpage>.</citation>
</ref>
<ref id="bibr93-0897190011431631">
<label> 93</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lyman</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Delgado</surname>
<given-names>DJ</given-names>
</name>
</person-group>. <article-title>Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma</article-title>. <source>Cancer</source>. <year>2003</year>;<volume>98</volume>:<fpage>2402</fpage>–<lpage>2409</lpage>.</citation>
</ref>
<ref id="bibr94-0897190011431631">
<label> 94</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lyman</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Morrison</surname>
<given-names>VA</given-names>
</name>
<name>
<surname>Dale</surname>
<given-names>CC</given-names>
</name>
<etal/>
</person-group>. <article-title>Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin’s lymphoma receiving CHOP chemotherapy</article-title>. <source>Leuk Lymphoma</source>. <year>2003</year>;<volume>44</volume>:<fpage>2069</fpage>–<lpage>2076</lpage>.</citation>
</ref>
<ref id="bibr95-0897190011431631">
<label> 95</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morrison</surname>
<given-names>VA</given-names>
</name>
<name>
<surname>Picozzi</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin’s lymphoma receiving initial CHOP chemotherapy: a risk factor analysis</article-title>. <source>Clin Lympoma</source>. <year>2001</year>;<volume>2</volume>:<fpage>47</fpage>–<lpage>56</lpage>.</citation>
</ref>
<ref id="bibr96-0897190011431631">
<label> 96</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>rawford</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Armitage</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. National Comprehensive Cancer Network Myeloid Growth Factors Guidelines. 2011 Version 1. <comment>[Online]. [cited Jun 2 2011]</comment>. <ext-link ext-link-type="uri" xlink:href="http://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf">http://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf</ext-link>
</citation>
</ref>
<ref id="bibr97-0897190011431631">
<label> 97</label>
<citation citation-type="book">
<collab collab-type="author">National Institutes of Health</collab>. Filgrastim label. <comment>[Online]. [cited Jun 9 2011]</comment>. <ext-link ext-link-type="uri" xlink:href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=16952">http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=16952</ext-link>
</citation>
</ref>
<ref id="bibr98-0897190011431631">
<label> 98</label>
<citation citation-type="book">
<collab collab-type="author">National Institutes of Health</collab>. Pegfilgrastim label. <comment>[Online]. [cited Jun 9 2011]</comment>. <ext-link ext-link-type="uri" xlink:href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=16131">http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=16131</ext-link>
</citation>
</ref>
<ref id="bibr99-0897190011431631">
<label> 99</label>
<citation citation-type="book">
<collab collab-type="author">National Institutes of Health</collab>. Sargramostim label. <comment>[Online]. [cited Jun 9 2011]</comment>. <ext-link ext-link-type="uri" xlink:href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=18715">http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=18715</ext-link>
</citation>
</ref>
<ref id="bibr100-0897190011431631">
<label>100</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lyman</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Kuderer</surname>
<given-names>NM</given-names>
</name>
</person-group>. <article-title>The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia</article-title>. <source>Crit Rev Oncol Hematol</source>. <year>2004</year>;<volume>50</volume>:<fpage>129</fpage>–<lpage>146</lpage>.</citation>
</ref>
<ref id="bibr101-0897190011431631">
<label>101</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Khatcheressian</surname>
<given-names>J</given-names>
</name>
</person-group>, <article-title>Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline</article-title>. <source>J Clin Oncol</source>. <year>2006</year>;<volume>24</volume>:<fpage>3187</fpage>–<lpage>3205</lpage>.</citation>
</ref>
<ref id="bibr102-0897190011431631">
<label>102</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crawford</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dale</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Lyman</surname>
<given-names>GH</given-names>
</name>
</person-group>. <article-title>Chemotherapy induced neutropenia: risks, consequences, and new directions for its management</article-title>. <source>Cancer</source>. <year>2004</year>;<volume>100</volume>:<fpage>228</fpage>–<lpage>237</lpage>.</citation>
</ref>
<ref id="bibr103-0897190011431631">
<label>103</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trillet-Lenoir</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Manegold</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy</article-title>. <source>Eur J Cancer</source>. <year>1993</year>;<volume>29A</volume>:<fpage>319</fpage>–<lpage>324</lpage>.</citation>
</ref>
<ref id="bibr104-0897190011431631">
<label>104</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vogel</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Wojtukiewicz</surname>
<given-names>MZ</given-names>
</name>
<name>
<surname>Carroll</surname>
<given-names>RR</given-names>
</name>
<etal/>
</person-group>. <article-title>First and subsequent cycle use of pegfilfrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study</article-title>. <source>J Clin Oncol</source>. <year>2005</year>;<volume>23</volume>:<fpage>1178</fpage>–<lpage>1184</lpage>.</citation>
</ref>
<ref id="bibr105-0897190011431631">
<label>105</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crawford</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ozer</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Stoller</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer</article-title>. <source>N Engl J Med</source>. <year>1991</year>;<volume>325</volume>:<fpage>164</fpage>–<lpage>170</lpage>.</citation>
</ref>
<ref id="bibr106-0897190011431631">
<label>106</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muhonen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Jantunen</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Pertovaara</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) for treatment of metastatic breast cancer: A randomized study</article-title>. <source>Am J Clin Oncol</source>. <year>1996</year>;<volume>19</volume>:<fpage>232</fpage>–<lpage>234</lpage>.</citation>
</ref>
<ref id="bibr107-0897190011431631">
<label>107</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pettengell</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gurney</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Radford</surname>
<given-names>JA</given-names>
</name>
<etal/>
</person-group>. <article-title>Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin’s lymphoma: a randomized controlled trial</article-title>. <source>Blood</source>. <year>1992</year>;<volume>80</volume>:<fpage>1430</fpage>–<lpage>1436</lpage>.</citation>
</ref>
<ref id="bibr108-0897190011431631">
<label>108</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fossa</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Kaye</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Mead</surname>
<given-names>GM</given-names>
</name>
<etal/>
</person-group>. <article-title>Fligrastim during combination chemotherapy of patients with poor prognosis metastatic germ cell malignancy</article-title>. <source>J Clin Oncol</source>. <year>1998</year>;<volume>16</volume>:<fpage>716</fpage>–<lpage>724</lpage>.</citation>
</ref>
<ref id="bibr109-0897190011431631">
<label>109</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lyman</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Dale</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Wolff</surname>
<given-names>DA</given-names>
</name>
<etal/>
</person-group>. <article-title>Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review</article-title>. <source>J Clin Oncol</source>. <year>2010</year>;<volume>28</volume>:<fpage>2914</fpage>–<lpage>2924</lpage>.</citation>
</ref>
<ref id="bibr110-0897190011431631">
<label>110</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Green</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Koelbl</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Baselga</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>A randomized double blind multicenter phase III study of fixed-dose single-adminstration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy</article-title>. <source>Ann Oncol</source>. <year>2003</year>;<volume>14</volume>:<fpage>29</fpage>–<lpage>35</lpage>.</citation>
</ref>
<ref id="bibr111-0897190011431631">
<label>111</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnston</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Blackwell</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy</article-title>. <source>J Clin Oncol</source>. <year>2000</year>;<volume>18</volume>:<fpage>2522</fpage>–<lpage>2528</lpage>.</citation>
</ref>
<ref id="bibr112-0897190011431631">
<label>112</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hermansen-Kobulnicky</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Widerholt</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Chewning</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Adverse effect monitoring: opportunity for patient care and pharmacy practice</article-title>. <source>J Am Pharm Assoc</source>. <year>2004</year>;<volume>44</volume>:<fpage>75</fpage>–<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr113-0897190011431631">
<label>113</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haynes</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Ackloo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sahota</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Interventions for enhancing medication adherence</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2008</year>;<volume>2</volume>:<fpage>CD000011</fpage>. doi : 10.1002/14651858.CD000011.pub3.</citation>
</ref>
<ref id="bibr114-0897190011431631">
<label>114</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valgus</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jarr</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Pharmacist-led, interdisciplinary model for delivery of supportive care in the ambulatory cancer clinic setting</article-title>. <source>J Oncol Pract</source>. <year>2010</year>;<volume>6</volume>:<fpage>e1</fpage>–<lpage>e4</lpage>.</citation>
</ref>
<ref id="bibr115-0897190011431631">
<label>115</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barbour</surname>
<given-names>SY</given-names>
</name>
</person-group>. <article-title>Caring for the treatment-experienced breast cancer patient: the pharmacist’s role</article-title>. <source>Am J Health-Syst Pharm</source>. <year>2008</year>;<volume>65</volume>(<issue>suppl 3</issue>):<fpage>S16</fpage>–<lpage>S22</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>